Retinal abnormality and visual disturbances occur in Thiamine Responsive Megaloblastic Anemia (TRMA), an autosomal recessive disorder caused by mutations in the human thiamine transporter-1 (hTHTR-1). Human retinal pigment epithelial (hRPE) cells play a pivotal role in supplying thiamine to the highly metabolically active retina but nothing is known about the mechanism, regulation, or biological processes involved in thiamine transport in these cells. To address these issues, we used human-derived retinal pigment epithelial ARPE-19 cells to characterize the thiamine uptake process. Thiamine uptake is energy- and temperature- dependent, pH sensitive, Na+-independent, saturable at both the nanomolar (apparent Km= 30 ± 5 nM) and the micromolar (apparent Km= 1.72 ± 0.3 µM) concentration ranges, specific for thiamine, and sensitive to sulfhydryl group inhibition. While the diuretic amiloride caused a concentration-dependent inhibition in thiamine uptake, the anti-trypanosomal drug, melarsoprol, failed to affect the uptake process. Both the hTHTR-1 and -2 are expressed in ARPE-19 cells as well as native human retinal tissue with expression of the former being significantly higher than that of the latter. Uptake of thiamine was adaptively regulated by extracellular substrate level via transcriptionally mediated mechanisms that involve both hTHTR-1 and hTHTR-2; it was also regulated by an intracellular Ca2+/CaM -mediated pathway. Confocal imaging of living ARPE-19 cells expressing TRMA-associated hTHTR-1 mutants (D93H, S143F and G172D) showed various expression phenotypes. These results demonstrate for the first time the existence of a specialized and regulated uptake process for thiamine in a cellular model of human retinal pigment epithelia that involves hTHTR-1 and hTHTR-2. Further, clinically relevant mutations in hTHTR-1 lead to impaired cell surface expression or function of the transporter in retinal epithelial ARPE-19 cells.